Naturally mutagenic sequence diversity in a human type II topoisomerase
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2302064120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Afif F Bandak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205. Hauptthemen laut MEDLINE: Mutagens, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
Type II topoisomerases transiently cleave duplex DNA as part of a strand passage mechanism that helps control chromosomal organization and superstructure. Aberrant DNA cleavage can result in genomic instability, and how topoisomerase activity is controlled to prevent unwanted breaks is poorly understood. Using a genetic screen, we identified mutations in the beta isoform of human topoisomerase II (hTOP2β) that render the enzyme hypersensitive to the chemotherapeutic agent etoposide. Several of these variants were unexpectedly found to display hypercleavage behavior in vitro and to be capable of inducing cell lethality in a DNA repair–deficient background; surprisingly, a subset of these mutations were also observed in TOP2B sequences from cancer genome databases. Using molecular dynamics simulations and computational network analyses, we found that many of the mutations obtained from the screen map to interfacial points between structurally coupled elements, and that dynamical modeling could be used to identify other damage-inducing TOP2B alleles present in cancer genome databases. This work establishes that there is an innate link between DNA cleavage predisposition and sensitivity to topoisomerase II poisons, and that certain sequence variants of human type II topoisomerases found in cancer cells can act as DNA-damaging agents. Our findings underscore the potential for hTOP2β to function as a clastogen capable of generating DNA damage that may promote or support cellular transformation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
- Pharmaceutical Sciences Department, University of Illinois College of Pharmacy, Rockford, IL 61107.
- Biomedical Sciences Department, University of Illinois College of Medicine, Rockford, IL 61107.
ORCID-Profile: Afif F Bandak, Tim R Blower, James M Berger
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- HHS | National Institutes of Health
- HHS | NIH | National Cancer Institute
Zitieren
APA
Bandak, A. F., Blower, T. R., Nitiss, K. C., Gupta, R., Lau, A. Y., Guha, R., Nitiss, J. L., & Berger, J. M. (2023). Naturally mutagenic sequence diversity in a human type II topoisomerase. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2302064120
Vancouver
Bandak AF, Blower TR, Nitiss KC, Gupta R, Lau AY, Guha R, et al. Naturally mutagenic sequence diversity in a human type II topoisomerase. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2302064120
BibTeX
@article{Bandak2023,
author = {Bandak, Afif F and Blower, Tim R and Nitiss, Karin C and Gupta, Raveena and Lau, Albert Y and Guha, Ria and Nitiss, John L and Berger, James M},
title = {Naturally mutagenic sequence diversity in a human type II topoisomerase},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2302064120}
}
EUVIMED